Abstract:
A pharmaceutical composition includes a preparation of virus-like particles (VLPs) obtained from the gastrointestinal tract of a subject and a pharmaceutically-acceptable carrier. The VLPs can include bacteriophages, eukaryotic viruses, or gene transfer agents. A VLP composition may be administered to a subject having, or at risk of having dysbiosis, in an amount effective to amelio-rate at least one symptom or clinical sign of dysbiosis. A VLP composition also may be administered to a subject in preparation for administering a source of bacteria, to improve the receptivity of subject's gut to source of bacteria.
Abstract:
A system for hearing assistance devices to assist hearing aid fitting applied to individual differences in hearing impairment. The system is also usable for assisting fitting and use of hearing assistance devices for listeners of music. The method uses a subjective space approach to reduce the dimensionality of the fitting problem and a non-linear regression technology to interpolate among hearing aid parameter settings. This listener-driven method provides not only a technique for preferred aid fitting, but also information on individual differences and the effects of gain compensation on different musical styles.
Abstract:
The present disclosure provides methods for treating a hearing disorder associated with maladaptive neuroplasticity, reduction of inhibition, shift of excitation-to-inhibition balance, changes in central gain, and/or changes in neural sensitivity in a subject by inhibiting the function and/or production of tumor necrosis factor alpha (TNF-α) in the subject. The present disclosure provides methods of administering to the subject a TNF-α inhibitory agent in an amount effective to treat the subject for a hearing disorder associated with maladaptive neuroplasticity, reduction of inhibition, shift of excitation-to-inhibition balance, changes in central gain, and/or changes in neural sensitivity. TNF-α inhibitory agents of the subject disclosure include agents that inhibit the function TNF-α, inhibit the production of TNF-α, inhibit TNF-α signaling, inhibit TNF-α expression, or inhibit TNF-α signaling pathway genes in the subject. The present disclosure also provides methods for treating a hearing disorder associated with maladaptive neuroplasticity, reduction of inhibition, shift of excitation-to-inhibition balance, changes in central gain, and/or changes in neural sensitivity in a subject by disrupting one or more alleles of a TNF-α signaling pathway gene in a cell of the subject.
Abstract:
A system for hearing assistance devices to assist hearing aid fitting applied to individual differences in hearing impairment. The system is also usable for assisting fitting and use of hearing assistance devices for listeners of music. The method uses a subjective space approach to reduce the dimensionality of the fitting problem and a non-linear regression technology to interpolate among hearing aid parameter settings. This listener-driven method provides not only a technique for preferred aid fitting, but also information on individual differences and the effects of gain compensation on different musical styles.
Abstract:
An interval observer based on an equivalent circuit-thermal model for lithium-ion batteries is presented. State of charge-temperature-dependent parameters are considered as unknown but bounded uncertainties in a single cell model. A parallel and a series arrangement of five cells are used for observer design, where cell heterogeneity is accounted for through the uncertainty bounding functions.
Abstract:
An interval observer based on an equivalent circuit-thermal model for lithium-ion batteries is presented. State of charge-temperature-dependent parameters are considered as unknown but bounded uncertainties in a single cell model. A parallel and a series arrangement of five cells are used for observer design, where cell heterogeneity is accounted for through the uncertainty bounding functions.
Abstract:
A light converting nanoparticle represented by Chemical Formula 1, AXx Chemical Formula 1 wherein, in Chemical Formula 1, A comprises an alkaline metal element, an alkaline-earth metal element, or a combination thereof, X comprises a halogen element, and x is 1 or 2 and is selected such that Chemical Formula 1 is electrically neutral, and a dopant substituted for a portion of A, wherein the dopant comprises Tl+, In+, Pb2+, Bi3+, Ag+, Cu+, Eu2+, Mn2+, or a combination thereof, wherein a content of the dopant is less than 15 mole percent, based on a total moles of A, wherein the light converting nanoparticle has a particle diameter of less than or equal to about 100 nanometers, and the light converting nanoparticle has a structure, cubic structure, an orthorhombic structure, a rhombic dodecahedron structure, or a combination thereof.
Abstract:
An indium-containing quantum dot including a compound represented by Chemical Formula 1: In1-xMxA Chemical Formula 1 wherein, in Chemical Formula 1, M is aluminum, gallium, yttrium, or scandium, A is nitrogen, phosphorous, arsenic, antimony, bismuth, or a combination thereof, and X is greater than or equal to 0 and less than 1, wherein the indium-containing quantum dot includes fluorine and oxygen to bonded to a surface of the indium-containing quantum dot, wherein an amount of the fluorine is greater than or equal to about 10 atomic percent based on a total number of indium atoms in the indium-containing quantum dot as determined by Rutherford backscattering analysis, and wherein an amount of the oxygen is about 5 atomic percent to about 50 atomic percent based on the total number of indium atoms included in the quantum dot as determined by Rutherford backscattering analysis.
Abstract:
A method for generating a non-thermal plasma having predetermined ozone concentration includes: providing an at least approximately closed volume as a reaction region; activating a plasma source and generating a non-thermal plasma in the reaction region. The plasma is held in the reaction region at least until a predetermined ozone concentration is reached or the ozone concentration falls below a predetermined upper limit for the ozone concentration.
Abstract:
Described herein are methods and systems for proposing coordination framework compounds, such as crystalline porous materials, crystalline open frameworks, reticular chemistry compounds, metal-organic framework (MOF) compounds, covalent organic framework (COF) compounds, zeolitic imidazolate framework (ZIF) compounds, and combinations thereof. Also described herein are coordination framework compounds produced by same and sorbent systems including the coordination framework compounds. The methods and systems described herein combine machine learning and chemistry to propose chemically valid and performance improved coordination framework compounds that meet different goals of material discovery.